Rocket Pharmaceuticals
RCKT
173 hedge funds and large institutions have $2.75B invested in Rocket Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 52 reducing their positions, and 29 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 52
2% less funds holding
Funds holding: 177 → 173 (-4)
3.44% less ownership
Funds ownership: 103.84% → 100.4% (-3.4%)
10% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 29
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
19% less capital invested
Capital invested by funds: $3.4B → $2.75B (-$649M)
55% less call options, than puts
Call options by funds: $4.13M | Put options by funds: $9.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$53.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48M |
| 3 |
State Street
Boston,
Massachusetts
|
+$25.1M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$16.6M |
| 5 |
BlackRock
New York
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$73.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$34.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$29.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$23.8M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$17M |
RCKT Hedge Fund Activity: Q1 2021 in Review
173 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2021, worth a combined $2.75B — down 19% from $3.4B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of RCKT and 26 opened new positions — a net loss of 3 holders — while 52 trimmed existing stakes and 75 added.
The largest buyer was Wellington Management Group, adding an estimated $53.7M. The largest seller was RTW Investments, cutting an estimated $73.8M.
- 173 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2021, down from 177 in Q4 2020.
- Funds reported $2.75B of Rocket Pharmaceuticals stock for Q1 2021, down 19% quarter-over-quarter.
- 26 funds opened new Rocket Pharmaceuticals positions in Q1 2021 and 29 closed out, a net change of -3 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2021 was Wellington Management Group, an estimated $53.7M added.
- The largest Rocket Pharmaceuticals seller in Q1 2021 was RTW Investments, an estimated $73.8M sold.
Based on aggregated 13F filings for Q1 2021.